As for the secondary analysis comparing ALB to other benzimidazole derivatives, disproportionality analysis revealed an over-reporting of certain serious adverse events, ranked by decreasing adjusted ROR: leukopenia (aROR 14.3, 95% CI 4.25–89.0), bone marrow failure and hypoplastic anemias (aROR 11.1, 95% CI 2.31–199), hepatic disorders (aROR 5.70, 95% CI 3.88–8.59) and hepatitis (aROR 4.82, 95% CI 2.98–8.16). Here, ALB is linked to Bone marrow hypocellularity.